RÉSUMÉ
PURPOSE: Colonoscopic surveillance is recommended for individuals with familial colorectal cancer (CRC). However, the appropriate screening interval has not yet been determined. The aim of this randomized trial was to compare a 3-year with a 6-year screening interval. PATIENTS AND METHODS: Individuals between ages 45 and 65 years with one first-degree relative with CRC age < 50 years or two first-degree relatives with CRC were selected. Patients with zero to two adenomas at baseline were randomly assigned to one of two groups: group A (colonoscopy at 6 years) or group B (colonoscopy at 3 and 6 years). The primary outcome measure was advanced adenomatous polyps (AAPs). Risk factors studied included sex, age, type of family history, and baseline endoscopic findings. RESULTS: A total of 528 patients were randomly assigned (group A, n = 262; group B, n = 266). Intention-to-treat analysis showed no significant difference in the proportion of patients with AAPs at the first follow-up examination at 6 years in group A (6.9%) versus 3 years in group B (3.5%). Also, the proportion of patients with AAPs at the final follow-up examination at 6 years in group A (6.9%) versus 6 years in group B (3.4%) was not significantly different. Only AAPs at baseline was a significant predictor for the presence of AAPs at first follow-up. After correction for the difference in AAPs at baseline, differences between the groups in the rate of AAPs at first follow-up and at the final examination were statistically significant. CONCLUSION: In view of the relatively low rate of AAPs at 6 years and the absence of CRC in group A, we consider a 6-year surveillance interval appropriate. A surveillance interval of 3 years might be considered in patients with AAPs and patients with ≥ three adenomas.
Sujet(s)
Polypes adénomateux/diagnostic , Polypes adénomateux/génétique , Coloscopie , Tumeurs colorectales/diagnostic , Tumeurs colorectales/génétique , Surveillance de la population/méthodes , Tumeurs colorectales/prévention et contrôle , Dépistage précoce du cancer , Femelle , Humains , Mâle , Adulte d'âge moyen , Facteurs de risque , Facteurs tempsRÉSUMÉ
BACKGROUND AND AIMS: Adalimumab is an effective therapy for induction and maintenance of Crohn's disease. However, results in clinical trials don't necessarily reflect daily clinical practice. Therefore, we assessed real-life long-term clinical response to adalimumab in a large population-based cohort and identified clinical parameters affecting response METHODS: All consecutive patients in North-Holland that started adalimumab between 2003 and 2011 were included, of which medical charts were reviewed. Response to induction therapy was assessed after 3months. Sustained benefit of maintenance therapy was calculated from Kaplan-Meier survival tables depicting ongoing adalimumab treatment. Regression analyses were performed to identify factors predicting response to adalimumab therapy. RESULTS: In total 438 Crohn's patients started adalimumab with 92.5% response to the induction phase. After 1year 83.3% showed sustained benefit of maintenance treatment, followed by 74.0% after 2years. Nevertheless, one third of patients were in steroid-free remission at the end of their follow-up. Response to induction was negatively affected by longer disease duration (OR 1.05; p<0.01) and strictures (OR 3.73; p=0.04). Increased CRP levels predicted higher rates of initial response (OR 0.31; p<0.01). Concomitant thiopurines in the first 6months of adalimumab treatment decreased the risk to fail maintenance therapy (HR 0.69, p=0.05). Previous infliximab therapy did not affect response to adalimumab, however dose escalation was more often deemed necessary (p<0.01). CONCLUSION: Adalimumab was successful in the majority of patients, with 10% loss of response per subsequent year. Concomitant thiopurines might improve adalimumab maintenance treatment.
Sujet(s)
Anti-inflammatoires/usage thérapeutique , Anticorps monoclonaux humanisés/usage thérapeutique , Maladie de Crohn/traitement médicamenteux , Adalimumab , Adulte , Femelle , Humains , Estimation de Kaplan-Meier , Mâle , Études rétrospectives , Résultat thérapeutiqueRÉSUMÉ
UNLABELLED: The recent addition of immunoglobulin (Ig)G4-associated cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chronic cholangiopathies has created the clinical need for reliable methods to discriminate between IAC and the more common cholestatic entities, primary (PSC) and secondary sclerosing cholangitis. The current American Association for the Study of Liver Diseases practice guidelines for PSC advise on the measurement of specific Ig (sIg)G4 in PSC patients, but interpretation of elevated sIgG4 levels remains unclear. We aimed to provide an algorithm to distinguish IAC from PSC using sIgG analyses. We measured total IgG and IgG subclasses in serum samples of IAC (n = 73) and PSC (n = 310) patients, as well as in serum samples of disease controls (primary biliary cirrhosis; n = 22). sIgG4 levels were elevated above the upper limit of normal (ULN = >1.4 g/L) in 45 PSC patients (15%; 95% confidence interval [CI]: 11-19). The highest specificity and positive predictive value (PPV; 100%) for IAC were reached when applying the 4 × ULN (sIgG4 > 5.6 g/L) cutoff with a sensitivity of 42% (95% CI: 31-55). However, in patients with a sIgG4 between 1 × and 2 × ULN (n = 38/45), the PPV of sIgG4 for IAC was only 28%. In this subgroup, the sIgG4/sIgG1 ratio cutoff of 0.24 yielded a sensitivity of 80% (95% CI: 51-95), a specificity of 74% (95% CI: 57-86), a PPV of 55% (95% CI: 33-75), and a negative predictive value of 90% (95% CI: 73-97). CONCLUSION: Elevated sIgG4 (>1.4 g/L) occurred in 15% of patients with PSC. In patients with a sIgG4 >1.4 and <2.8 g/L, incorporating the IgG4/IgG1 ratio with a cutoff at 0.24 in the diagnostic algorithm significantly improved PPV and specificity. We propose a new diagnostic algorithm based on IgG4/IgG1 ratio that may be used in clinical practice to distinguish PSC from IAC.
Sujet(s)
Angiocholite sclérosante/immunologie , Angiocholite/immunologie , Immunoglobuline G/sang , Adulte , Sujet âgé , Angiocholite/diagnostic , Angiocholite sclérosante/diagnostic , Femelle , Humains , Immunoglobuline G/classification , Mâle , Adulte d'âge moyen , Valeur prédictive des testsRÉSUMÉ
BACKGROUND: Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD). The aim of this study was to assess the IBD phenotype associated with PSC in a large well-phenotyped population-based PSC cohort using endoscopic and histopathologic criteria. METHODS: PSC cases were identified and ascertained, fulfilling well-established criteria, in 39 hospitals in a geographically defined region of The Netherlands. IBD location was recorded according to the Montreal Classification. As this classification does not consider segmental inflammation, backwash ileitis, or rectal sparing, an additional subgroup analysis was performed in 80 cases and 80 age- and sex-matched IBD controls, reviewing all endoscopy and pathology reports filed between 2000 and 2010. RESULTS: In all, 380 (66%) of a total of 579 PSC patients had coexistent IBD, mainly ulcerative colitis (UC) (75%). Overall, 207 (83%) of the PSC-UC patients had a pancolitis, 32 (13%) a left-sided colitis, and 9 (4%) a proctitis only. Seventy (95%) PSC-Crohn's disease (CD) patients had an (ileo)colitis and four (5%) ileitis only. In the subgroup analysis 53 (66%) PSC-UC patients were identified, 24 (30%) PSC-CD patients, and three (4%) PSC-IBD-U patients. Fifty (94%) PSC-UC patients had a pancolitis, compared with 32 (62%) matched UC patients (P < 0.001). Left-sided colitis was seen in 16 (31%) UC controls and in one PSC-UC patient (P < 0.001). Backwash ileitis and rectal sparing were rare findings (<10%) in the cohorts under study. CONCLUSIONS: IBD in PSC patients represents a distinct phenotype in that pancolitis is observed in 94% of PSC-UC and colitis in 96% of PSC-CD patients. Backwash ileitis and rectal sparing were rare findings in the PSC-UC patients.
Sujet(s)
Angiocholite sclérosante/complications , Maladies inflammatoires intestinales/complications , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Études cas-témoins , Loi du khi-deux , Enfant , Enfant d'âge préscolaire , Angiocholite sclérosante/anatomopathologie , Rectocolite hémorragique/complications , Rectocolite hémorragique/anatomopathologie , Côlon/anatomopathologie , Femelle , Humains , Iléite/complications , Iléite/anatomopathologie , Iléum/anatomopathologie , Nourrisson , Maladies inflammatoires intestinales/anatomopathologie , Mâle , Adulte d'âge moyen , Phénotype , Rectite/complications , Rectite/anatomopathologie , Rectum/anatomopathologie , Statistique non paramétrique , Jeune adulteRÉSUMÉ
OBJECTIVES: Drug-induced pancreatitis (DIP) is considered a relative rare disease entity, perhaps due to lack of recognition. The objective of this study was to evaluate the prevalence of pancreatitis-associated drugs in a Dutch cohort of patients admitted for acute pancreatitis (AP) and to identify the proportion AP possibly attributable to the use of drugs. METHODS: This was a multicenter observational study (EARL study). Etiology, disease course, use of pancreatitis-associated drugs at hospital admittance, and discontinuation of these drugs were evaluated. Drugs were scored by means of an evidence-based DIP classification system. RESULTS: The first documented hospital admissions of 168 patients were analyzed. In all, 70 out of 168 (41.6%; 95% confidence interval (CI): 34.5-49.2%) patients used pancreatitis-associated drugs at admission. In 26.2% (44/168; 95% CI: 20.1-33.3%) of cases, at least one class I pancreatitis-associated drug was used. Possibly DIP was present in 12.5% (21/168; 95% CI: 8.3-18.4%); in less than half of these patients (9/21 or 42.9%; 95% CI: 24.5-63.5%), the prescribed drugs were actually discontinued, with no recurrence of AP later on. Among the remaining 12 patients without discontinuation of their drugs use and in absence of an alternative etiologic cause of AP, 8 patients used a class I pancreatitis-associated drug, representing 4.8% (8/168, 95% CI: 2.4-9.1%) of the total study population. CONCLUSIONS: In this series, a remarkably high percentage of patients who were admitted because of an attack of AP used pancreatitis-associated drugs. Physicians should be more aware of the possibility of DIP in patients with otherwise unexplained AP and act appropriately by discontinuation of the drug.
Sujet(s)
Pancréatite/induit chimiquement , Médicaments sur ordonnance/effets indésirables , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Anti-inflammatoires/effets indésirables , Anticholestérolémiants/effets indésirables , Antihypertenseurs/effets indésirables , Études de cohortes , Femelle , Humains , Mâle , Adulte d'âge moyen , Pays-Bas , Médicaments sur ordonnance/classification , Tomodensitométrie , Jeune adulteSujet(s)
Abdomen/anatomopathologie , Diarrhée/étiologie , Panniculite péritonéale/diagnostic , Anti-inflammatoires/usage thérapeutique , Antinéoplasiques hormonaux/usage thérapeutique , Humains , Mâle , Adulte d'âge moyen , Palpation , Panniculite péritonéale/complications , Panniculite péritonéale/traitement médicamenteux , Prednisone/usage thérapeutique , Tamoxifène/usage thérapeutiqueRÉSUMÉ
AIM: To assess the prevalence and location of advanced neoplasia in patients undergoing colonoscopy, and to compare the yield per indication. METHODS: In a multicenter colonoscopy survey (n = 18 hospitals) in the Amsterdam area (Northern Holland), data of all colonoscopies performed during a three month period in 2005 were analyzed. The location and the histological features of all colonic neoplasia were recorded. The prevalence and the distribution of advanced colorectal neoplasia and differences in yield between indication clusters were evaluated. Advanced neoplasm was defined as adenoma > 10 mm in size, with > 25% villous features or with high-grade dysplasia or cancer. RESULTS: A total of 4623 eligible patients underwent a total colonoscopy. The prevalence of advanced neoplasia was 13%, with 281 (6%) adenocarcinomas and 342 (7%) advanced adenomas. Sixty-seven percent and 33% of advanced neoplasia were located in the distal and proximal colon, respectively. Of all patients with right-sided advanced neoplasia (n = 228), 51% had a normal distal colon, whereas 27% had a synchronous distal adenoma. Ten percent of all colonoscopies were performed in asymptomatic patients, 7% of whom had advanced neoplasia. In the respective procedure indication clusters, the prevalence of right-sided advanced neoplasia ranged from 11%-57%. CONCLUSION: One out of every 7-8 colonoscopies yielded an advanced colorectal neoplasm. Colonoscopy is warranted for the evaluation of both symptomatic and asymptomatic patients.
Sujet(s)
Tumeurs du côlon/diagnostic , Tumeurs du côlon/anatomopathologie , Coloscopie/méthodes , Tumeurs colorectales/diagnostic , Tumeurs colorectales/anatomopathologie , Adénocarcinome/diagnostic , Adénocarcinome/épidémiologie , Adénocarcinome/anatomopathologie , Adénomes/diagnostic , Adénomes/épidémiologie , Adénomes/anatomopathologie , Anémie/étiologie , Côlon/anatomie et histologie , Côlon/anatomopathologie , Tumeurs colorectales/épidémiologie , Latéralité fonctionnelle , Humains , Pays-Bas/épidémiologie , Prévalence , Perte de poidsRÉSUMÉ
MR enteroclysis is becoming a very important imaging modality in the workup and follow-up of small bowel diseases. The technique has many advantages, including the absence of ionizing radiation, ability to control luminal distension, superior tissue characterization, multiplanar capabilities, and mural and extramural visualization. These capabilities can be obtained with a simple protocol showing excellent agreement with conventional enteroclysis. In 29 (18 with new or known Crohn's disease) of the 50 patients pathology was detected, with a very good clinical correlation. In 14 patients MR enteroclysis data altered the therapeutic strategy. This contributes to the acceptance of this modality as a primary tool in small bowel diseases.